Search
  • Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2020 year
    07
    03 day
    Ferring and Winhealth reached strategic partnership of Glypressin®

    (July 7, 2020, Hangzhou) Ferring Pharmaceuticals and Hong Kong Winhealth Pharmaceutical Group Co., Ltd.  announced that they have reached a strategic partnership agreement. Ferring grants the commercial rights of its key product, Glypressin® (Terlipressin Acetate for Injection) to Winhealth for the distribution and promotion in mainland China. The partnership will come into effect on July 1, while Ferring remains as the license holder and manufacturer of the product.

     

    Ferring and Winhealth reached strategic partnership of Glypressin® (Terlipressin Acetate for Injecti


    Glypressin® (Terlipressin Acetate for Injection), with the chemical name of triglyceride-8-lysine-vasopressin, was launched in Germany in 1981 and introduced to China in 1996. It has been the first-line pharmaceutical treatment for complications caused by portal hypertension of advanced liver cirrhosis, such as esophageal and gastric variceal bleeding, ascites due to liver cirrhosis, hepatorenal syndrome, etc. In addition, it has been explicitly recommended by international and domestic Guidelines and Consensus including The 2012 AASLD Guide for Diagnosis and Treatment of Cirrhosis Ascites: the Diagnosis and Treatment of Hepatorenal Syndrome, EASL Guide for Clinical Practice, China Guide for Clinical Practice of Intrahepatic Portosystemic Shunt via Jugular Vein (2019 Version), Guide for Diagnosis and Treatment of Cirrhosis (2019 Version), Guide for Diagnosis and Treatment of Ascites Due to Cirrhosis and Related Complications, etc.

     

    China has more than 400 million patients with liver diseases , among which 103 million have viral hepatitis, 60 million have alcoholic liver disease, and 200 million have non-alcoholic fatty liver disease [1-2]. Although the incidence rate of viral liver disease has declined in recent years, the number of patients with non-alcoholic fatty liver disease is increasing steadily and will possibly exceed 310 million in 2030 [3]. Viral hepatitis, alcoholic hepatitis and non-alcoholic hepatitis may progress to cirrhosis. The survey and analysis results in China in the recent decade indicates that the esophageal and gastric varices bleeding as the most common complication of portal hypertension has an incidence rate of up to 55.6% [4]. The potential patient population is estimated to be 200 million. The IMS data of 2018 shows that the annual growth rate of terlipressin acetate products was 41% [5]. With broad market penetration and great commercial potential, terlipressin acetate is expected to achieve faster growth driven by the academic efforts and wide coverage, and to grow into a blockbuster product in this field.

     

    “In the past decade, Ferring has been offering innovative solutions to Chinese patients. I am proud that we introduced Glypressin® to help thoughts of Chinese patients suffering from Bleeding Oesophageal Varices,” said Eric Breumier, CEO of Ferring China. “With the significant unmet medical needs, I am very pleased to partner with Winhealth with its displayed leadership and footprint in Gastroenterology. We expect that Winhealth will build upon the commitment Ferring has made and serve more patients in the future. As a specialty innovator, Ferring is committed to keeping innovating and producing life-changing medicine in reproductive medicine and maternal health, selected urology and gastro diseases to help Chinese patients live better lives.”

     

    'Winhealth has always been committed to introducing high-quality international health products and medical technologies into China. We have two major business segments, the EPD and ITD, with hepatology being one of the key focus areas for the former. Ferring Pharmaceuticals is just the right partner we look forward to working with, and Glypressin® being the right product we have been searching for. Together with our other products, Glypressin® will build upon our success and form a strong synergy with our existing portfolio and commercial infrastructure. As such, we are really full of expectation and excitement about this cooperation', said Mr. Jack Wang, founder / chairman / CEO of Winhealth, ' Currently, there are still considerable number of  unmet needs for liver disease patients in China. To this end, Ferring and Winhealth will work closely together and focus on the patients' needs in order to provide impactful benefit to the liver disease patients in China and contribute to the success of Healthy China program. '    

     

    The signing of this agreement marks the establishment of a long-term strategic partnership between the two companies, which will, as they always do, leverage their professional influence in the industry to promote the continual development of China's health care and to contribute a positive force to China's health industry.

     

    About Ferring Pharmaceuticals


    Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

     

    Learn more at www.ferring.com, or connect with us on Wechat.

     

    About WINHEALTH PHARMA

     

    Hongkong Winhealth Pharma Group Co. Ltd. is an innovative pharmaceutical company based in Hong Kong and facing to mainland China, focusing on importing and commercializing proprietary therapeutics that address areas of severe unmet or underserved medical need in the Greater China market. The company consists of two major divisions, or EPD and ITD, of which the former covers respiratory and infectious disease, cardiovascular, hepatology, dermatology and urology, while the latter is rare disorders-centered. By providing fully-integrated local development, regulatory and commercialization services to international pharmaceutical enterprises, Winhealth has grown into one of the well-known CDCO (Contract Development and Commercialization Organization) organization in China. Its clients covers some world's top 500 pharmaceutical MNEs. Headquartered in Hong Kong, China, WINHEALTH has operation centres and offices in Hangzhou, Shanghai, Beijing, Guangzhou, Hainan, Tokyo and Munich. For more information please go to http://www.winhealth.hk

     

    Reference

     

    [1] WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease: the major impact of China [J]. Hepatology, 2014, 60(6):2099-2108.

    [2] MOKDAD AA, LOPEZ AD, SHAHRAZ S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis [J]. BMC Medicine, 2014, 12:145.

    [3] ESTES C, ANSTEE QM, TERESA ARIAS – LOSTE M, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016 – 2030 [J]. J Hepatol, 2018. [ Epub ahead of print]

    [4] Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS), Minimally Invasive Intervention Cooperation Group of Chinese Society of Gastroenterology, Emergency Intervention Professional Committee of Chinese College of Interventionalists etc. Consensus on Clinical Application of Hepatic Venous Pressure Gradient in China (2018) [J]. Journal of Clinical Hepatobiliary Disease, 2018, 34 (12): 2526 – 2536

    [5] Mat201809 IMS data.

     

    Forward-Looking Statements

     

    This release contains forward-looking statements, which reflect the current beliefs and expectations of Winhealth Pharma’s management. Based on expectations and assumptions about the available information, the statements may involve several known and unknown risks and uncertainties that could cause our future results  differ significantly from those expressed or implied by such forward-looking statements. The risks and uncertainties include domestic and international macroeconomic conditions such as overall market conditions and changes in interest rates and currency exchange rates, which are particularly applicable to forward-looking statements relating to products. Product risks and uncertainties include, but are not limited to, the completion and termination of clinical trials; obtaining of regulatory approval; statements and concerns about product safety and effectiveness; technical progresses; adverse results of major litigations; medical reform and changes in domestic and foreign laws and regulations. In addition, there are manufacturing and marketing risks for existing products, including but not limited to capacity failure to meet demands, availability to raw materials, market entry of competitive products, and force majeure. The company undertakes no intention or obligation to update or modify any forward-looking statements, whether as a result of new information, future events or otherwise.


    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.